Showing results (2561-2570 of 10,445) with videos related to

Sort By:
Pageof 1,045
AIDS (London, England)|September 27, 2005
Replicative fitness of historical and recent HIV-1 isolates suggests HIV-1 attenuation over timeKevin K Ariën, Ryan M Troyer, Youssef Gali, et al.
AIDS (London, England)|May 21, 2005
Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapineCesar Fisac, Emilio Fumero, Manuel Crespo, et al.
AIDS (London, England)|July 10, 2010
High prevalence of reduced bone mineral density in primary HIV-1-infected menMarlous L Grijsen, Saskia M E Vrouenraets, Radjin Steingrover, et al.
AIDS (London, England)|December 11, 2014
Vitamin D supplementation is associated with reduced immune activation levels in HIV-1-infected patients on suppressive antiretroviral therapyVéronique Fabre-Mersseman, Roland Tubiana, Laura Papagno, et al.
AIDS (London, England)|September 4, 1998
A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study GroupC Cohen, D A Revicki, A Nabulsi, et al.
AIDS (London, England)|December 15, 2010
Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical careHeidi M Crane, Carl Grunfeld, James H Willig, et al.
AIDS (London, England)|April 1, 1991
High antibody titres in mice with polymethylmethacrylate nanoparticles as adjuvant for HIV vaccinesF Stieneker, J Kreuter, J Löwer
AIDS (London, England)|April 26, 2011
Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reductionTakara L Stanley, Julian Falutz, Jean-Claude Mamputu, et al.
AIDS (London, England)|January 12, 2012
Efficacy and safety of once-daily ritonavir-boosted darunavir and abacavir/lamivudine for treatment-naïve patients: a pilot studyTakeshi Nishijima, Kunihisa Tsukada, Katsuji Teruya, et al.
AIDS (London, England)|February 26, 2013
Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infectionTricia H Burdo, Allison Weiffenbach, Steven P Woods, et al.
Pageof 1,045